vs
NATIONAL RESEARCH CORP（NRC）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是NATIONAL RESEARCH CORP的2.0倍（$69.8M vs $35.2M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 5.1%，领先378.9%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -4.6%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -0.2%）
NRC Health（原国家研究公司）是一家美国医疗健康企业，1981年成立，总部位于内布拉斯加州林肯市。公司主要在美加两国提供医疗健康相关产品及订阅式解决方案，深耕区域医疗健康服务领域。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
NRC vs RIGL — 直观对比
营收规模更大
RIGL
是对方的2.0倍
$35.2M
营收增速更快
RIGL
高出25.8%
-4.6%
净利率更高
RIGL
高出378.9%
5.1%
两年增速更快
RIGL
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $35.2M | $69.8M |
| 净利润 | $1.8M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 13.3% | 33.2% |
| 净利率 | 5.1% | 384.0% |
| 营收同比 | -4.6% | 21.2% |
| 净利润同比 | -72.6% | 1769.2% |
| 每股收益（稀释后） | $49.58 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NRCRIGL
| Q4 25 | $35.2M | $69.8M | ||
| Q3 25 | $34.6M | $69.5M | ||
| Q2 25 | $34.0M | $101.7M | ||
| Q1 25 | $33.6M | $53.3M | ||
| Q4 24 | $36.9M | $57.6M | ||
| Q3 24 | $35.8M | $55.3M | ||
| Q2 24 | $35.0M | $36.8M | ||
| Q1 24 | $35.3M | $29.5M |
净利润NRCRIGL
| Q4 25 | $1.8M | $268.1M | ||
| Q3 25 | $4.1M | $27.9M | ||
| Q2 25 | $-106.0K | $59.6M | ||
| Q1 25 | $5.8M | $11.4M | ||
| Q4 24 | $6.6M | $14.3M | ||
| Q3 24 | $5.7M | $12.4M | ||
| Q2 24 | $6.2M | $-1.0M | ||
| Q1 24 | $6.4M | $-8.2M |
毛利率NRCRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率NRCRIGL
| Q4 25 | 13.3% | 33.2% | ||
| Q3 25 | 22.4% | 40.9% | ||
| Q2 25 | 4.7% | 60.1% | ||
| Q1 25 | 25.6% | 23.9% | ||
| Q4 24 | 26.0% | 28.9% | ||
| Q3 24 | 22.3% | 25.4% | ||
| Q2 24 | 25.3% | 1.2% | ||
| Q1 24 | 24.8% | -23.6% |
净利率NRCRIGL
| Q4 25 | 5.1% | 384.0% | ||
| Q3 25 | 11.9% | 40.2% | ||
| Q2 25 | -0.3% | 58.6% | ||
| Q1 25 | 17.2% | 21.5% | ||
| Q4 24 | 17.8% | 24.9% | ||
| Q3 24 | 15.9% | 22.5% | ||
| Q2 24 | 17.6% | -2.8% | ||
| Q1 24 | 18.0% | -27.9% |
每股收益（稀释后）NRCRIGL
| Q4 25 | $49.58 | $14.11 | ||
| Q3 25 | $0.18 | $1.46 | ||
| Q2 25 | $-0.01 | $3.28 | ||
| Q1 25 | $0.25 | $0.63 | ||
| Q4 24 | $0.27 | $0.82 | ||
| Q3 24 | $0.24 | $0.70 | ||
| Q2 24 | $0.26 | $-0.06 | ||
| Q1 24 | $0.27 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.1M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $14.0M | $391.5M |
| 总资产 | $134.9M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资NRCRIGL
| Q4 25 | $4.1M | $155.0M | ||
| Q3 25 | $2.2M | $137.1M | ||
| Q2 25 | $5.3M | $108.4M | ||
| Q1 25 | $2.5M | $77.1M | ||
| Q4 24 | $4.2M | $77.3M | ||
| Q3 24 | $3.5M | $61.1M | ||
| Q2 24 | $485.0K | $49.1M | ||
| Q1 24 | $1.7M | $49.5M |
总债务NRCRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | $48.7M | $60.0M | ||
| Q2 24 | $33.3M | $60.0M | ||
| Q1 24 | $35.2M | $60.0M |
股东权益NRCRIGL
| Q4 25 | $14.0M | $391.5M | ||
| Q3 25 | $14.3M | $117.6M | ||
| Q2 25 | $21.3M | $81.9M | ||
| Q1 25 | $29.7M | $18.6M | ||
| Q4 24 | $31.3M | $3.3M | ||
| Q3 24 | $34.6M | $-14.6M | ||
| Q2 24 | $40.2M | $-29.9M | ||
| Q1 24 | $36.9M | $-31.7M |
总资产NRCRIGL
| Q4 25 | $134.9M | $513.6M | ||
| Q3 25 | $135.7M | $242.5M | ||
| Q2 25 | $141.4M | $206.7M | ||
| Q1 25 | $135.2M | $176.0M | ||
| Q4 24 | $132.5M | $164.0M | ||
| Q3 24 | $131.8M | $139.4M | ||
| Q2 24 | $119.1M | $128.4M | ||
| Q1 24 | $120.9M | $126.5M |
负债/权益比NRCRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | 1.41× | — | ||
| Q2 24 | 0.83× | — | ||
| Q1 24 | 0.95× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.2M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $6.1M | — |
| 自由现金流率自由现金流/营收 | 17.2% | — |
| 资本支出强度资本支出/营收 | 3.2% | — |
| 现金转化率经营现金流/净利润 | 3.99× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $15.7M | — |
8季度趋势，按日历期对齐
经营现金流NRCRIGL
| Q4 25 | $7.2M | $22.0M | ||
| Q3 25 | $13.8M | $24.0M | ||
| Q2 25 | $-1.1M | $30.5M | ||
| Q1 25 | $6.6M | $-893.0K | ||
| Q4 24 | $6.4M | $14.5M | ||
| Q3 24 | $9.4M | $21.7M | ||
| Q2 24 | $6.8M | $302.0K | ||
| Q1 24 | $12.0M | $-5.0M |
自由现金流NRCRIGL
| Q4 25 | $6.1M | — | ||
| Q3 25 | $10.2M | — | ||
| Q2 25 | $-4.1M | — | ||
| Q1 25 | $3.7M | — | ||
| Q4 24 | $1.9M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $1.5M | — | ||
| Q1 24 | $7.9M | — |
自由现金流率NRCRIGL
| Q4 25 | 17.2% | — | ||
| Q3 25 | 29.4% | — | ||
| Q2 25 | -12.2% | — | ||
| Q1 25 | 10.9% | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 21.8% | — | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | 22.4% | — |
资本支出强度NRCRIGL
| Q4 25 | 3.2% | — | ||
| Q3 25 | 10.4% | — | ||
| Q2 25 | 8.8% | — | ||
| Q1 25 | 8.9% | — | ||
| Q4 24 | 12.0% | — | ||
| Q3 24 | 4.5% | — | ||
| Q2 24 | 15.0% | — | ||
| Q1 24 | 11.7% | — |
现金转化率NRCRIGL
| Q4 25 | 3.99× | 0.08× | ||
| Q3 25 | 3.34× | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | 1.15× | -0.08× | ||
| Q4 24 | 0.97× | 1.01× | ||
| Q3 24 | 1.66× | 1.75× | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 1.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
